Study Reveals 80% of Lung Cancer Deaths in Brazil Linked to Smoking

Regulations by 2FIRSTS.ai
May.17.2024
Study Reveals 80% of Lung Cancer Deaths in Brazil Linked to Smoking
Study at GRELL 2024 reveals 80% of Brazil lung cancer deaths linked to smoking, causing concerns for public health.

According to a report from Brazilian media SBTNEWS on May 16th, a study presented at the Latin American Cancer Epidemiology and Registration Organization annual meeting (GRELL 2024) held by the Cancer Foundation in Switzerland revealed that 80% of male and female lung cancer deaths in Brazil are related to smoking (nicotine dependence). Alfredo Scaff, medical advisor at the Cancer Foundation, stated that the purpose of this study is to present data that can help prevent the disease to society.

 

A standard journalistic translation is: Skaf believes that there is a direct relationship between lung cancer and smoking habits, stating that "strictly speaking, smoking is currently the main cause of cancer worldwide, especially in Brazil.

 

There is controversy surrounding the use of e-cigarettes as a method to quit smoking, according to Scarf. In most cases, he believes it only leads to a habit of addiction to smoking. Scarf has warned that e-cigarettes may further increase the death rate from lung cancer caused by smoking. He also reminds people to be aware that nicotine is the most addictive substance in legal drugs.

 

A study has shown that the annual cost of lung cancer in Brazil reaches up to 9 billion Reais, including direct medical expenses, loss of productivity, and care for patients. However, the tobacco industry only covers 10% of the total expenses related to lung cancer in Brazil, amounting to 125 billion Reais.

 

Skaf pointed out that smoking not only leads to lung cancer but also to tooth decay, damage to the mouth and throat, chronic obstructive pulmonary disease, hypertension, acute myocardial infarction, and stroke. All of these contribute to increased direct costs in the public domain, such as treatment expenses, as well as indirect costs like productivity losses, budget expenditures, and so on.

 

The National Cancer Institute of Brazil predicts that this year there will be 14,000 new cases of lung cancer in women and 18,000 new cases in men. Additionally, the research found that the majority of patients, whether male (63.1%) or female (63.9%), seek medical attention when the disease has already reached an advanced stage. This is a widespread phenomenon across all regions of Brazil.

 

Researchers from the Cancer Foundation analyzed global data from the International Agency for Research on Cancer (IARC) and found that if current smoking patterns continue, the incidence and mortality rates of lung cancer are projected to increase by over 65% and 74% respectively by the year 2040 compared to 2022.

 

In the southern region, smoking is very common. The incidence of lung cancer in the southern region is higher, with 24.14 cases per 100,000 for men and 15.54 cases per 100,000 for women, exceeding the national average of 12.73 cases for men and 9.26 cases for women.

 

The incidence rates of lung cancer in men are lower than the national average in the southern and northeastern regions, while the incidence rates in women in the southern, northeastern, and southeastern regions are 8.27 cases, 8.46 cases, and 8.92 cases per 100,000 people, respectively, also lower than the national average. In all age groups, the male lung cancer mortality rate in the southern region is the highest in the country. According to research, the lung cancer mortality rate in men aged 40-59 in the southern region is 16.03 cases per 100,000 people, while for those aged 60 and above, it is 132.26 cases per 100,000 people.

 

According to information from the Brazilian news agency, Brazil is facing an even more serious issue as many patients are already in the late stages of their illness when seeking treatment. This is not only the case for male patients (63.1%), but also for female patients (63.9%). This is a trend seen across all regions of Brazil.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa plans to publish its first vapor products directory on November 16, 2026, after which products not listed will be prohibited from sale or offer for sale in the state. The Department of Revenue expects to begin penalty enforcement on December 17, following an initial 21-business-day period focused on compliance education. Under House File 2677, retailers, distributors and wholesalers selling unlisted products face civil penalties of $300 per product per day, while manufacturers face $1,000 per product per day. Eligibility extends to FDA-authorized products and certain products meeting historical marketing and pending PMTA requirements. The directory program resumed after a federal appeals court vacated a preliminary injunction in July 2026.
Regulations
Nov.05
Pennsylvania Lists 163 Vape Products Eligible for Sale, Including Vuse and JUUL; Previously Pending Chinese Brands Such as OXBAR Remain Absent, While Unlisted Products Including Geek Bar Face Enforcement From October 19
Pennsylvania Lists 163 Vape Products Eligible for Sale, Including Vuse and JUUL; Previously Pending Chinese Brands Such as OXBAR Remain Absent, While Unlisted Products Including Geek Bar Face Enforcement From October 19
Pennsylvania begins enforcing its electronic nicotine delivery system (ENDS) directory restrictions on October 19, 2026. The October 18 directory contained 163 product records from seven manufacturers, including Vuse, JUUL, NJOY, Logic and Naked 100. Geek Bar, RAZ and Lost Mary were absent. BAT, Altria, Japan Tobacco and JUUL collectively accounted for 112 records, or 68.7%, while Imperial Brands' blu had no listings. The directory included 15 disposable vape records, 40 bottled e-liquids and 10 products labeled 0mg, but no open-system refillable devices. Twenty-two manufacturer certifications remained under review. Four Logic models corresponding to Smoore's pending records were listed under the brand owner, while LYCO, OXBAR and Boulder/Rock had no approved directory entries.
Regulations
Oct.19
New York City Opens Lottery for 55 Vape Retail License Slots Across 23 Community Districts, Including 28 in Brooklyn
New York City Opens Lottery for 55 Vape Retail License Slots Across 23 Community Districts, Including 28 in Brooklyn
New York City's Department of Consumer and Worker Protection (DCWP) opened applications on November 2, 2026, for a lottery covering tobacco and electronic cigarette retail dealer licenses, with a deadline of 5 p.m. New York local time on November 30. According to the city's October 1 notice, 55 electronic cigarette retail license slots are available across 23 community districts, including 28 in Brooklyn, alongside 322 tobacco retail license slots across 41 districts. Businesses must enter the lottery and, if invited, complete licensing requirements within 65 days. New York City continues to restrict e-cigarette retail sales to tobacco-flavored or unflavored products, while city retail licenses do not replace FDA product marketing authorization.
Market
Nov.04
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14